Erie Retina Research, a retina-focused clinical research provider for ophthalmology drug and device development, has been purchased by Lexitas Pharma Services, a QHP-backed pharma services platform.

The add-on places a specialty retina research business inside a clinical research services company serving life sciences development programs.

The target works in the retina segment of ophthalmology clinical research, a category tied to products for diseases and conditions affecting the back of the eye.

Retina studies can involve drug candidates, medical devices and related treatment technologies, placing providers such as Erie Retina Research within the outsourced development infrastructure used by companies running eye-care programs.

The asset's focus makes the transaction a specialized add-on within ophthalmology clinical research, not a general healthcare provider acquisition.

Lexitas Pharma Services is the operating acquirer in the transaction, while QHP provides private equity backing to the platform.

The deal gives Lexitas a provider focused on retina research and keeps the platform's acquisition activity within pharmaceutical services, clinical development support and healthcare services under QHP backing.

For deal readers, the transaction is a sponsor-backed healthcare services add-on involving a platform acquirer and a niche clinical research provider.

The named asset is concentrated in retina programs, giving the acquisition a defined therapeutic focus within outsourced ophthalmology research for drug and device development.